4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $502,800 | -3.4% | 39,481 | +37.0% | 0.00% | 0.0% |
| Q2 2023 | $520,334 | +5.0% | 28,814 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $495,656 | -48.5% | 28,814 | -31.7% | 0.00% | 0.0% |
| Q4 2022 | $961,569 | +105.5% | 42,185 | -27.6% | 0.00% | 0.0% |
| Q3 2022 | $468,000 | +31.5% | 58,256 | +14.0% | 0.00% | 0.0% |
| Q2 2022 | $356,000 | -12.3% | 51,108 | +90.2% | 0.00% | 0.0% |
| Q1 2022 | $406,000 | +50.4% | 26,872 | +118.1% | 0.00% | +100.0% |
| Q4 2021 | $270,000 | -14.0% | 12,320 | +5.8% | 0.00% | 0.0% |
| Q3 2021 | $314,000 | +24.1% | 11,648 | +11.0% | 0.00% | 0.0% |
| Q2 2021 | $253,000 | -44.4% | 10,495 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $455,000 | +4.6% | 10,495 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $435,000 | – | 10,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |